Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bilateral Internal Pallidum Stimulation in Primary Generalized Dystonia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Princess Beatrix Fund, The Netherlands
Information provided by:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier:
NCT00272246
First received: January 4, 2006
Last updated: NA
Last verified: January 2006
History: No changes posted
  Purpose

Primary generalized dystonia, also called idiopathic torsion dystonia or dystonia musculorum deformans is a disabling neurological condition which usually starts in childhood, mostly in a lower limb and spreads to other body parts as the disease progresses. Medical treatment is usually ineffective and most patients become wheelchair bound or even bedridden. Recently several case series and one RCT reported favourable results of bilateral deep brain stimulation (DBS) of the globus pallidus internus (GPi) for primary generalized dystonias. However, the number of patients treated with bilateral GPi stimulation is still limited. Therefore, we propose a RCT to investigate whether bilateral DBS of the GPi is an effective and safe treatment in patients with primary generalized dystonia.


Condition Intervention Phase
Dystonia
Primary Generalized Dystonia
Procedure: deep brain stimulation of the internal globus pallidus
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):

Primary Outcome Measures:
  • change in BFMDRS-motor score from baseline to six months after stimulation equipment implantation

Secondary Outcome Measures:
  • BFMDRS-disability score
  • MOS-SF-36 (Medical Outcome Scale)
  • GOS (Global Outcome Scale)
  • Neuropsychological and neuropsychiatric validated scales
  • Questionnaire designed for the registration of the number and extent of morbidity due to the surgical
  • procedure, stimulation equipment and active stimulation

Estimated Enrollment: 24
Study Start Date: February 2005
Estimated Study Completion Date: December 2007
Detailed Description:

Study design and methods:

This is a randomised, double-blind, placebo-controlled, multicentre study comparing the effect of bilateral DBS of the GPi with placebo in patients with invalidating primary generalized dystonia. After inclusion in the study (see in/exclusioncriteria), a preoperative formal baseline assessment is performed. Within six weeks after the inclusion the patients undergo the stereotactic implantation of the stimulation equipment in the GPi. Immediately after surgery the patients are randomly allocated to direct stimulation (treatment group) or delayed stimulation (control group), in which the stimulator will se switched on 0 Volt before discharge from the hospital by an independent neurologist or neurosurgeon. The patients in both groups are able to control whether the stimulation is active (>0 Volt) or not. In this way the patients and the assessors are blinded. In each centre the postoperative care of the patients will take place according to a stratified stimulation parameter protocol which assures comparable information in both groups. Six months postoperatively, the first formal outcome assessment is performed by the same blinded assessor. After completion of this assessment the stimulators in the control group are activated by an independent neurologist or neurosurgeon. From this moment, all 24 patients have active DBS. However, the patients and blinded assessor remain unaware of the result of the randomisation. All patients are followed for another six months after which the second outcome assessment is made by the same assessor. Four Dutch centres experienced in DBS have agreed to participate in the study. It is estimated that each centre will include at least 4 patients. Because these centra are geographically spread over the country patients can be operated and controlled nearby.

  Eligibility

Ages Eligible for Study:   12 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Invalidating primary generalized dystonia (BFMDRS-motor part >= 35)
  2. Disease duration >= 5 yrs
  3. Age at surgery between 12 and 60
  4. Insufficient improvement with pharmacological and physical therapy
  5. Signed informed consent, for patients < 19 yrs of age a written consent of the parent(s) or caretaker(s) is needed.

Exclusion Criteria:

  1. Mental retardation or dementia (MMSE <24)
  2. Depressive state (HADS>21)
  3. History of former stereotactic brain surgery
  4. Severe brain atrophy
  5. General surgical contraindications, such as uncontrolled hypertension or diabetes mellitus, cardiovascular or pulmonary risks, disturbances of bloodclotting.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272246

Contacts
Contact: Elisabeth MJ Foncke, MD 0031205669111 ext 58966 e.m.foncke@amc.uva.nl
Contact: Hans Speelman, MD,PhD 0031205669111 ext 63963 j.d.speelman@amc.uva.nl

Locations
Netherlands
Department of Neurology, Movement Disorders Center Recruiting
Amsterdam, Netherlands, 1100 DD
Contact: Elisabeth MJ Foncke, MD    0031205669111 ext 58966    e.m.foncke@amc.uva.nl   
Principal Investigator: Elisabeth MJ Foncke, MD         
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Princess Beatrix Fund, The Netherlands
Investigators
Study Chair: Hans Speelman, PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00272246     History of Changes
Other Study ID Numbers: DYSPAS
Study First Received: January 4, 2006
Last Updated: January 4, 2006
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
dystonia

Additional relevant MeSH terms:
Dystonia
Dystonic Disorders
Central Nervous System Diseases
Dyskinesias
Movement Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on November 19, 2014